Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer
Author:
Funder
Guangzhou Municipal Science and Technology Project
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pharmacology
Reference47 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020
2. Androgen deprivation therapy for prostate cancer;Singer;Expert Opin. Pharmacother.,2008
3. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis;Scher;J. Clin. Oncol.,2005
4. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer;Watson;Nat. Rev. Cancer,2015
5. Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice;Ceballos;Antimicrob. Agents Chemother.,2011
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine;Cancer Letters;2024-03
2. Water extract of sporoderm-broken spores of Ganoderma lucidum elicits dual antitumor effects by inhibiting p-STAT3/PD-L1 and promoting ferroptosis in castration-resistant prostate cancer;Journal of Functional Foods;2024-02
3. P53 together with ferroptosis: a promising strategy leaving cancer cells without escape;Acta Biochimica et Biophysica Sinica;2023-12-09
4. Cellular senescence: A potential mode of circular RNAs regulating prostate cancer;MedComm – Oncology;2023-12
5. Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance;Cancer Drug Resistance;2023-10-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3